The effects of EPO on non-small cell lung cancer (NSCLC) were conflicting: Merkle et al. reported that concurrent treatment with EPO decreased cisplatin-induced caspase-3, leading to less apoptosis72; however, Frille et al. reported that EPO did not affect cisplatin-induced apoptosis of NSCLC73. The gene discussed is CASP3; the disease is non-small cell lung carcinoma.